QUOIN PHARMACEUTICALS LT-ADR (QNRX)
US74907L3006 - ADR
Taking everything into account, QNRX scores 2 out of 10 in our fundamental rating. QNRX was compared to 568 industry peers in the Biotechnology industry. QNRX may be in some trouble as it scores bad on both profitability and health. QNRX has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
QNRX had negative earnings in the past year.
In the past year QNRX has reported a negative cash flow from operations.
QNRX had negative earnings in each of the past 5 years.
In the past 5 years QNRX always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of QNRX (-58.92%) is comparable to the rest of the industry.
QNRX has a Return On Equity (-110.74%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -58.92% | ||
| ROE | -110.74% | ||
| ROIC | N/A |
ROA(3y)-122%
ROA(5y)-105.72%
ROE(3y)-1177.47%
ROE(5y)-750.96%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for QNRX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
QNRX has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, QNRX has more shares outstanding
The debt/assets ratio for QNRX is higher compared to a year ago.
2.2 Solvency
QNRX has an Altman-Z score of -6.14. This is a bad value and indicates that QNRX is not financially healthy and even has some risk of bankruptcy.
QNRX's Altman-Z score of -6.14 is on the low side compared to the rest of the industry. QNRX is outperformed by 66.19% of its industry peers.
A Debt/Equity ratio of 0.43 indicates that QNRX is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.43, QNRX is doing worse than 72.39% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.43 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.14 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
QNRX has a Current Ratio of 3.35. This indicates that QNRX is financially healthy and has no problem in meeting its short term obligations.
QNRX has a Current ratio of 3.35. This is comparable to the rest of the industry: QNRX outperforms 41.06% of its industry peers.
A Quick Ratio of 3.35 indicates that QNRX has no problem at all paying its short term obligations.
QNRX has a Quick ratio (3.35) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.35 | ||
| Quick Ratio | 3.35 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 69.04% over the past year.
EPS 1Y (TTM)69.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.9%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 25.89% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y79.28%
EPS Next 2Y36.44%
EPS Next 3Y25.89%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for QNRX. In the last year negative earnings were reported.
Also next year QNRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as QNRX's earnings are expected to grow with 25.89% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.44%
EPS Next 3Y25.89%
5. Dividend
5.1 Amount
QNRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
QUOIN PHARMACEUTICALS LT-ADR
NASDAQ:QNRX (12/19/2024, 6:29:51 PM)
After market: 0.5904 -0.06 (-8.72%)0.6468
+0.08 (+14.99%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners4.15%
Inst Owner Change-24.99%
Ins Owners482.24%
Ins Owner Change0.54%
Market Cap2.57M
Analysts80
Price Target4.59 (609.65%)
Short Float %1.93%
Short Ratio0.03
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.93%
Min EPS beat(2)-43.19%
Max EPS beat(2)37.32%
EPS beat(4)3
Avg EPS beat(4)8.95%
Min EPS beat(4)-43.19%
Max EPS beat(4)37.32%
EPS beat(8)6
Avg EPS beat(8)13.8%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.57%
PT rev (3m)-3.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)7.28%
EPS NY rev (3m)7.28%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.34 | ||
| P/tB | 0.37 | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.05
EYN/A
EPS(NY)-1.42
Fwd EYN/A
FCF(TTM)-2.01
FCFYN/A
OCF(TTM)-2.01
OCFYN/A
SpS0
BVpS1.88
TBVpS1.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -58.92% | ||
| ROE | -110.74% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-122%
ROA(5y)-105.72%
ROE(3y)-1177.47%
ROE(5y)-750.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.43 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.35 | ||
| Quick Ratio | 3.35 | ||
| Altman-Z | -6.14 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)69.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.9%
EPS Next Y79.28%
EPS Next 2Y36.44%
EPS Next 3Y25.89%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y5.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y10.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.13%
OCF growth 3YN/A
OCF growth 5YN/A